Boehringer Ingelheim Gmbh

Immuno Aktiengesellschaft

Dr. Karl Thomae Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

C. H. Boehringer Sohn

Boehringer Ingelheim Kg

Karl Thomae Gmbh

Ludwig Pichler

Walter Kobinger

Herbert Koppe

Werner Kummer

Helmut Stahle

Christian Lillie

Rudolf Hurnaus

Wolfgang Hoefke

Johann J Eibl

Wolfgang Grell

Wolfram Gaida

Robert Sauter

Joachim Mierau

Gunter Schingnitz

Gerhart Griss, Deceased

Hans Peter Schwarz

Dieter Hinzen

Rudolf Bauer

Gerhart Griss

Hans-Peter Schwarz

Kurt Schromm

Anton Mentrup

Claus S Schneider

Werner Traunecker

Peter Turecek

Ernst-Otto Renth

Manfred Reiffen

Dietrich Arndts

Michael Entzeroth

Ernst Otto Renth

Hanns Ihrig

Lothar Benedikter

An in vivo assay for determining the potential thrombogenic activity of a test compound entails pre-treating an animal with both a hepatoxin and either a bacterial agent (whole bacteria or bacterial toxins, including endotoxins) or a bacterial agent-induced cytokine, which pre-treatment enhances sensitivity to thrombogenic substances. The sensitized animal can be used in identifying a thrombogenic substance even when it is a weak potentiator of thrombogenesis, and in detecting smaller amounts of a strong potentiator.

Bioassay for thrombogenesis and rabbit model

A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen alone, in a dosage of about 10-1000 caseinolytic units/kg, can be used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like. Lys-plasminogen can also lessen cerebral edema which results from cerebral ischemia.

Treatment with lys-plasminogen of reperfusion injury and brain edema

There is disclosed the use of protein C and/or the activation peptide of protein C for preparing a pharmaceutical preparation having anti-nociceptive activity. This pharmaceutical preparation is useful in the treatment of painful conditions caused by acute or chronic inflammatory processes (such as rheumatoid arthritis, myositis, gastritis, colitis, inflammations in the urogenital tract).

Use of protein C or the activation peptide of protein C for preparing a

There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory disturbances, in particular with the proviso that the drug does not contain any immunoglobulin G.

Use of protein C in the treatment of purpura fulminans

A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen can used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like.

Prevention and treatment of ischemic events and reperfusion injury

The present invention relates to new 4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines of general formula II ##STR1## wherein the substituents are defined herein below, which compounds have valuable pharmacological properties, namely selective effects on the dopaminergic system which are achieved by stimulating (predominantly D2) dopamine receptors.

4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nucleic may each be substituted by 1 or 2 halogen atoms, R.sub.2 represents a hydrogen atom or an alkyl group, R.sub.3 represents a hydrogen atom, an alkyl group a cycloalkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the phenyl nucleus may be substituted by fluorine, chlorine or bromine atoms, R.sub.4 represents a hydrogen atom, an alkyl group, an alkyl or alkenyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group, the enantiomers and the acid addition salts thereof. The compounds of general formula I above in which one of the groups R.sub.1 or R.sub.3 or both groups R.sub.1 and R.sub.3 represent an acyl group are valuable intermediate products for preparing the other compounds of general formula I which have valuable pharmacological properties. The new compounds may be prepared using methods known per se.

Tetrahydro-benzthiazoles, the preparation thereof and their use as

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms.

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynylk group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms,

Compounds of the formula ##STR1## wherein A is ##STR2## and R is hydrogen, alkyl of 1 to 5 carbon atoms, alkanoyl of 1 to 5 carbon atoms, alkenyl of 3 to 5 carbon atoms, (alkoxy of 1 to 4 carbon atoms)carbonyl, or aralkyl of 7 to 11 carbon atoms optionally halo-substituted, and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.

Thienothiazole derivatives

Compounds of the formula ##STR1## wherein A and B, which may be the same or different, each represent methylene, (alkyl of 1 to 3 carbon atoms)-methylene, ethylene or (alkyl of 1 to 3 carbon atoms)-ethylene;

Fused-ring amino-pyrazines as bradycardiacs

Fused-ring amino-pyrazines as bradycardiac agents

Compounds of the formula ##STR1## wherein R is hydrogen or methyl, and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.

Substituted

Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, hydroxyl or amino;

Substituted 2-phenylamino-2-imidazolines and salts thereof

2-(2-Chloro-4-cyclopropyl-phenyl-imino)-imidazolidine, and acid addition

Growing community of inventors

Vienna, Austria

Ludwig Pichler